The number of patients exhibiting an ORR exceeded the threshold for moving into the second stage of Enchant-1, so is a material event for shareholders. Quite frankly, Feuerstein's column was a childish response as he couldn't stomach some news contrary to his negative outlook on SNTA. If he was interested in presenting an informed opinion, he would have noted the Enchant-1 data is for newly diagnosed patients, which differed from the previous Ganetespib data. He would have also mentioned that we are awaiting data for the Ganetespib + docetaxel arm. I like reading Feuerstein, but this was an unusually poor effort by him.